Stereotaxis Archives - Medical Design Sourcing

Stereotaxis opens new headquarters in St. Louis

Stereotaxis’ new headquarters are located in the historic Globe Building in downtown St. Louis. [Image courtesy of Globe Building]Surgical robotics company Stereotaxis (NYSE: STXS) is holding a grand opening today for its 45,000 ft² headquarters facility in downtown St. Louis.

The new headquarters is located in the renovated historic Globe Building in St. Louis’s growing Downtown North Urban Insight District. It’s an all-in-one facility housing research and development, advanced manufacturing, and distribution space for the company’s pipeline of robotic surgery technologies.

Stereotaxis more than 130 professionals in 10 countries worldwide. It designed its headquarters to accommodate significant long-term growth.

“Stereotaxis is delighted to inaugurate a modern new headquarters that serves as a foundation for years of progress and growth,” CEO David Fischel said in a news release.

“We appreciate the many community leaders who have support…

Study: Stereotaxis robotic technology reduces silent cerebral embolism during AFib ablation

Stereotaxis announced the positive results from a study of its robotic magnetic navigation system in atrial fibrillation ablation.

The multi-center, prospective study evaluated 166 patients with paroxysmal or persistent AFib who underwent pulmonary vein isolation using Stereotaxis’ robotic magnetic navigation (RMN) technology or manual contact force ablation catheters. All patients on the study received cerebral magnetic resonance imaging (MRI) within 48 hours before and after the ablation procedure to assess the possibility of cerebral embolism.

Get the full story on our sister site, Medical Tubing + Extrusion.

Stereotaxis forms partnership to advance electrophysiology robotics in China

Stereotaxis this week announced it has forged a broad collaboration with Shanghai Microport EP Medtech to advance technology innovation and commercial adoption of electrophysiology robotics in China.

The agreement combines MicroPort EP’s commercial and product expertise in China’s electrophysiology market and Sterotaxis’s Robotic Magnetic Navigation technology. Through the collaboration, MicroPort EP will be the exclusive distributor of StereoTaxis’s Robotic Magnetic Navigation system for electrophysiology in China. MicroPort will also pursue regulatory approvals for Stereotaxis’s innovations including the Genesis RMN system and other magnetic ablation catheters.

Stereotaxis’s robotic systems will also be integrated with MicroPort EP’s Columbus mapping system through the agreement. Both companies will work to develop a family of cardiac ablation and diagnostic catheters.

“I am very excited by the promise of this …

Stereotaxis up on Street-beating Q4 results

Shares of Stereotaxis (NYSE:STXS) shot up in morning trading today after the robotic surgery company reported Street-beating Q4 results and predicted double-digit revenue growth this year.

The St. Louis–based company, creator of robotic technologies for the treatment of cardiac arrhythmias, reported a loss of –$1.18 million, or –2¢ share, on sales of $6.82 million for the three months ended Dec. 31, 2020, versus a loss of $1.08 million, or –2¢ per share, on sales of $6.89 million in Q4 2019.

Earnings were a penny ahead of The Street, where analysts predicted a loss of –3¢ per share on sales of $6.03 million.

CEO David Fischel said 2020 was a year of significant progress, despite the challenges of the COVID-19 pandemic.

“The highlight of the year was receipt of FDA clearance for the Genesis RMN System and successful installations of the first systems in the United States and Europe. We begin 2021 with purchase orders for five robotic systems reflec…

Stereotaxis raises $15m

Stereotaxis (NYSE:STXS) announced that it entered into a securities purchase agreement to issue common stock for net proceeds of approximately $15 million.

St. Louis, Mo.-based Stereotaxis said in a news release that the agreement with certain funds managed by Consonance Capital Management will see it issue approximately 3.66 million shares of common stock at $4.10 per share.

According to the release, the purchase price reflects a 9% premium to Steriotaxis’ 10-day volume-weighted average trading price.

The company, which develops robotic technologies for the treatment of cardiac arrhythmias, expects the offering to take place on or about May 28, subject to closing conditions.

“We are excited to have Consonance Capital join us in our mission to improve patient care and positively transform interventional medicine with robotics,” Stereotaxis chairman & CEO David Fischel said in the release. “This financing is particularly m…